Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Lipids Health Dis ; 14: 43, 2015 May 08.
Article in English | MEDLINE | ID: mdl-25952508

ABSTRACT

BACKGROUND: Recent studies have shown that some glycosyltransferases are involved in the development of nonalcoholic fatty liver disease (NAFLD). The objective of this study was to explore the effect and mechanism of glycosyltransferase GLT8D2 on fatty liver. METHODS: Rat model of NAFLD was established by induction with high-fat-diet. The GLT8D2 expression in rat liver was examined using immunohistochemistry. Oil Red O staining and triglyceride assay were used to measure the effect of abnormal GLT8D2 expression on lipid accumulation in HepG2 cells. The expression levels of lipid metabolism-related key molecules, namely sterol regulatory element-binding protein-1c (SREBP-1c), stearoyl-coA desaturase (SCD), carnitine palmitoyltransferase-1 (CPT1) and microsomal triglyceride transfer protein (MTP), in HepG2 cells with abnormal GLT8D2 expression were determined by western blot analyses. RESULTS: The expression of GLT8D2 was higher in the liver of rats with NAFLD than in the control rats, and GLT8D2 was mainly located around lipid droplets in hepatocytes. GLT8D2 expression increased in steatosis HepG2 cells compared with that in normal HepG2 cells. GLT8D2 positively regulated lipid droplet accumulation and triglyceride content in HepG2 cells. Upregulation or knockdown of GLT8D2 had no effect on the expressions of SREBP-1c, SCD or CPT-1 proteins in HepG2 cells. However, GLT8D2 expression negatively regulated the expression of MTP protein in HepG2 cells. CONCLUSION: GLT8D2 participated in NAFLD pathogenesis possibly by negatively regulating MTP expression. Specific inhibition of GLT8D2 via an antagonistic strategy could provide a potential candidate approach for treatment of NAFLD.


Subject(s)
Non-alcoholic Fatty Liver Disease/enzymology , Animals , Blotting, Western , Carrier Proteins/metabolism , Disease Models, Animal , Hep G2 Cells/chemistry , Hep G2 Cells/enzymology , Humans , Lipids/analysis , Male , Non-alcoholic Fatty Liver Disease/etiology , Rats , Rats, Sprague-Dawley , Triglycerides/analysis , Triglycerides/metabolism
2.
Int J Mol Sci ; 14(11): 21435-46, 2013 Oct 29.
Article in English | MEDLINE | ID: mdl-24173238

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) is characterized by triglyceride (TG) accumulation in hepatocytes. Very low density lipoprotein (VLDL) is a major secretory product of the liver that transports endogenously synthesized TG. Disrupted VLDL secretion may contribute to the accumulation of TG in hepatocytes. ApoB100 (apolipoprotein B100) is a glycoprotein and an essential protein component of VLDL. Its glycosylation may affect VLDL assembly and secretion. However, which glycosyltransferase catalyzes apoB100 glycosylation is unknown. In this study, we cloned the GLT8D2 (glycosyltransferase 8 domain containing 2) gene from HepG2 cells and generated a series of plasmids for in vitro studies of its molecular functions. We discovered that GLT8D2 was localized in the ER, interacted with apoB100, and positively regulated the levels of apoB100 protein in HepG2 cells. Based on these results, we propose that GLT8D2 is a glycosyltransferase of apoB100 that regulates apoB100 levels in hepatocytes.


Subject(s)
Apolipoprotein B-100/biosynthesis , Fatty Liver/genetics , Glycosyltransferases/genetics , Hepatocytes/enzymology , Cloning, Molecular , Fatty Liver/enzymology , Fatty Liver/pathology , Gene Expression Regulation, Enzymologic , Glycosyltransferases/metabolism , Hep G2 Cells , Hepatocytes/pathology , Humans , Lipoproteins, VLDL/metabolism , Non-alcoholic Fatty Liver Disease , Triglycerides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...